Skip to Main Content

Evaluating ARIA in the treatment of Alzheimer’s disease with neuroimaging AI


2 mins

In the realm of medical research, the development of cutting-edge technologies has revolutionized our understanding and treatment of various diseases.


One such field is artificial intelligence (AI) neuroimaging detection and quantification, which may significantly impact the surveillance of Amyloid-Related Imaging Abnormalities (ARIA) that can be a side effect of recently approved pharmaceuticals being used to treat Alzheimer’s disease.